← Back to Search

Antioxidant

Resveratrol for Gulf War Syndrome (MINER Trial)

Phase 2
Waitlist Available
Led By Dena Davidson, Ph.D.
Research Sponsored by VISN 17 Center of Excellence
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Served on active military duty and deployed to the Persian Gulf region August 1990 - July 1991;
Female subjects of childbearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test and agree to use reliable method of birth control (for example, oral contraceptives or Norplant; a reliable barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam]; intrauterine devices; partner with vasectomy; or abstinence) during the study. Note that this inclusion criterion applies only to females of childbearing potential. Females of childbearing potential are defined as women not surgically sterilized and between menarche and 2 years post-menopause.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, mid (week 13) and post (week 26)
Awards & highlights

MINER Trial Summary

This study is evaluating whether resveratrol may help improve symptoms of Gulf War Illness.

MINER Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

MINER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, mid (week 13) and post (week 26)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, mid (week 13) and post (week 26) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in Cognitive Function
Change from baseline in Daily Functioning
Change from baseline in Mood
Secondary outcome measures
Change from baseline in Diffusion Tensor Imaging
Magnetic Resonance Imaging
Other outcome measures
Change from baseline in Pro-inflammatory cytokines

Side effects data

From 2013 Phase 2 trial • 24 Patients • NCT02114892
25%
Headache
8%
Sickness
8%
Abdominal pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Resveratrol
Placebo

MINER Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ResveratrolExperimental Treatment1 Intervention
Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment.
Group II: PlaceboPlacebo Group1 Intervention
Doses of placebo at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the placebo, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Resveratrol
Not yet FDA approved

Find a Location

Who is running the clinical trial?

VISN 17 Center of ExcellenceLead Sponsor
3 Previous Clinical Trials
587 Total Patients Enrolled
Texas A&M UniversityOTHER
137 Previous Clinical Trials
23,364 Total Patients Enrolled
1 Trials studying Gulf War Syndrome
80 Patients Enrolled for Gulf War Syndrome
Baylor UniversityOTHER
53 Previous Clinical Trials
65,014 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~10 spots leftby Mar 2025